Claims
- 1. A method of inhibiting or reducing fungal infection or fungal growth, comprising contacting the fungus or an object in contact with the fungus with an amount of a peptide or peptidomimetic comprising a sequence having 90% or more identity to a sequence defined as:
(i) P1, P2, P3, P4, P5, P6 or P6, P5, P4, P3, P2, P1; wherein P1 is d- or 1-Cha, d- or 1-Nal(2), d- or 1-(Phe-2,3,4,5,6-F), d- or 1-(Phe-3,4,5F), d- or 1-(Phe-4CF3), an amino acid that occupies a similar side chain space, or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene group, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, quinazoline group in the side chain; P2 is d- or 1-Cha, d- or 1-Nal(2), d- or 1-(Phe-2,3,4,5,6-F), d- or 1-(Phe-3,4,5F), d- or 1-(Phe-4CF3), d- or 1-Bpa, d- or 1-Phe4NO2, an amino acid that occupies a similar side chain space, or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, or quinazoline group in the side chain; P3, P4, P5 are any amino acid or one or more of P3, P4, P5 is a simple carbon chain such that the distance between P2 and P6 is about the same as the distance when each of P3, P4, P5 are amino acids; P6 is d- or 1-Bpa, d- or 1-Phe4NO2, any amino acid and d- or 1-Tyr, any amino acid and d- or 1-Phe, any amino acid, or nothing; (ii) or a prodrug thereof, sufficient to inhibit or reduce fungal infection or fungal growth.
- 2. The method of claim 1, wherein the peptide or peptidomimetic comprises a sequence of any one of the sequences set forth in Table 1, and has anti-fungal activity.
- 3. The method of claim 1, further comprising contacting with or exposing the fungus or object to a nucleic acid damaging agent or nucleic acid damaging treatment.
- 4. The method of claim 1, wherein the fungus or object is present in a subject.
- 5. The method of claim 1, wherein the fungus comprises a yeast, mold or slime.
- 6. The method of claim 5, wherein the yeast comprises Candida or Saccharomyces.
- 7. The method of claim 1, wherein the fungus or object is present in the environment, in a residential, commerical, industrial or community setting, or in an agricultural or horticultural setting.
- 8. A method of inhibiting or reducing contamination of an object or organism with a fungus comprising contacting the object or organism with an amount of a compound including a peptide or peptidomimetic comprising a sequence having 90% or more identity to a sequence defined as:
(i) P1, P2, P3, P4, P5, P6 or P6, P5, P4, P3, P2, P1; wherein P1 is d- or 1-Cha, d- or 1-Nal(2), d- or 1-(Phe-2,3,4,5,6-F), d- or 1-(Phe-3,4,5F), d- or 1-(Phe-4CF3), an amino acid that occupies a similar side chain space, or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene group, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, quinazoline group in the side chain; P2 is d- or 1-Cha, d- or 1-Nal(2), d- or 1-(Phe-2,3,4,5,6-F), d- or 1-(Phe-3,4,5F), d- or 1-(Phe-4CF3), d- or 1-Bpa, d- or 1-Phe4NO2, an amino acid that occupies a similar side chain space, or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, or quinazoline group in the side chain; P3, P4, P5 are any amino acid or one or more of P3, P4, P5 is a simple carbon chain such that the distance between P2 and P6 is about the same as the distance when each of P3, P4, P5 are amino acids; P6 is d- or 1-Bpa, d- or 1-Phe4NO2, any amino acid and d- or 1-Tyr, any amino acid and d- or 1-Phe, any amino acid, or nothing; (ii) or a prodrug thereof, sufficient to inhibit or reduce contamination of the object or organism.
- 9. The method of claim 8, further comprising contacting with or exposing the object or organism to a nucleic acid damaging agent or nucleic acid damaging treatment.
- 10. The method of claim 9, wherein the organism comprises a cell.
- 11. The method of claim 10, wherein the cell is a cultured cell.
- 12. The method of claim 9, wherein the organism is a human subject.
- 13. The method of claim 9, wherein the organism is a plant.
- 14. The method of claim 8, wherein the object is non-living.
- 15. The method of claim 8, wherein the object is an inorganic material or an organic material.
- 16. The method of claim 8, wherein the fungus comprises a yeast, mold or slime.
- 17. A method of treating fungal growth or fungal infection, comprising administering to a subject having or at risk of having fungal growth or fungal infection an amount of a compound comprising a sequence having 90% or more identity to a sequence defined as:
(i) P1, P2, P3, P4, P5, P6 or P6, P5, P4, P3, P2, P1; wherein P1 is d- or 1-Cha, d- or 1-Nal(2), d- or 1-(Phe-2,3,4,5,6-F), d- or 1-(Phe-3,4,5F), d- or 1-(Phe-4CF3), an amino acid that occupies a similar side chain space, or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene group, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, quinazoline group in the side chain; P2 is d- or 1-Cha, d- or 1-Nal(2), d- or 1-(Phe-2,3,4,5,6-F), d- or 1-(Phe-3,4,5F), d- or 1-(Phe-4CF3), d- or 1-Bpa, d- or 1-Phe4NO2, an amino acid that occupies a similar side chain space, or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, or quinazoline group in the side chain; P3, P4, P5 are any amino acid or one or more of P3, P4, P5 is a simple carbon chain such that the distance between P2 and P6 is about the same as the distance when each of P3, P4, P5 are amino acids; P6 is d- or 1-Bpa, d- or 1-Phe4NO2, any amino acid and d- or 1-Tyr, any amino acid and d- or 1-Phe, any amino acid, or nothing; (ii) or a prodrug thereof, effective to treat fungal growth or fungal infection.
- 18. The method of claim 17, wherein the peptide or peptidomimetic comprises a sequence of any one of the sequences set forth in Table 1, and has anti-fungal activity.
- 19. The method of claim 17, wherein the compound is administered locally, regionally or systemically.
- 20. The method of claim 17, wherein the compound is administered prior to, substantially contemparaneously with or following fungal contact, contamination, growth or infection.
- 21. The method of claim 17, wherein the compound is administered to skin, toe, nail, hair or a mucosal tissue.
- 22. The method of claim 17, wherein the fungal growth or fungal infection is present at least in part on the skin, toe, nail, hair or a mucosal tissue.
- 23. The method of claim 22, wherein the mucosal tissue is selected from the gastrointestinal tract, mouth, lungs, bronchial passages, nasal passages and sinuses, genito-urinary tract, and vagina.
- 24. The method of claim 17, wherein the fungal growth or fungal infection comprises a yeast or mold.
- 25. The method of claim 17, wherein the fungal growth or fungal infection is selected from dermatophytes, Coccidioides immitis, Histoplasma capsulatum, Candida albicans and Aspergillus fumigatus.
- 26. The method of claim 17, wherein the fungal growth or fungal infection causes onychomycosis; Jock-itch or athlete's foot; paracoccidioidomycosis; blastomycosis; mucormycosis; cryptococcosis; coccidioidomycosis; histoplasmosis; candidiasis; or aspergillosis
- 27. The method of claim 17, wherein the treatment results in improving the subject's condition.
- 28. The method of claim 27, wherein the improvement comprises reduced irritation, itching, inflammation, burning, hives, weeping, pruritus, excess discharge, discoloration, headache, or fatigue.
- 29. The method of claim 27, wherein the improvement comprises reduced susceptibility to or recurrence of fungal growth or fungal infection.
- 30. The method of claim 27, wherein the improvement comprises inhibiting a worsening or progression of the subject's condition.
- 31. The method of claim 27, further comprising administering a nucleic acid damaging agent, a nucleic acid damaging treatment, an anti-fungal agent, or an anti-fungal treatment to the subject.
- 32. The method of claim 31, wherein the agent or treatment comprises a drug.
- 33. The method of claim 32, wherein the drug comprises a chemotherapeutic drug.
- 34. The method of claim 32, wherein the drug has an anti-fungal activity or an anti-fungal function.
- 35. The method of claim 32, wherein the drug is a systemic drug or a topical drug.
- 36. The method of claim 32, wherein the drug is selected from a chemical class comprising: an allylamine, azole, polyene, pyrimidine, tetraene, thiocarbamate, sulfonamide, a glucan synthesis inhibitor and a benzoic acid compound.
- 37. The method of claim 32, wherein the drug is selected from amrolfine, butenafine, naftifine, terbinafine, ketoconazole, fluconazole, elubiol, econazole, econaxole, itraconazole, isoconazole, imidazole, miconazole, sulconazole, clotrimazole, enilconazole, oxiconazole, tioconazole, terconazole, butoconazole, thiabendazole, voriconazole, saperconazole, sertaconazole, fenticonazole, posaconazole, bifonazole, flutrimazole, nystatin, pimaricin, amphotericin B, flucytosine, natamycin, tolnaftate, mafenide, dapsone, caspofungin, actofunicone, griseofulvin, potassium iodide, Gentian Violet, ciclopirox, ciclopirox olamine, haloprogin, undecylenate, silver sulfadiazine, undecylenic acid, undecylenic alkanolamide and Carbol-Fuchsin.
- 38. The method of claim 32, wherein the drug comprises 5-fluorouracil (5-FU), rebeccamycin, adriamycin (ADR), bleomycin (Bleo), pepleomycin, a cisplatin derivative, camptotecin (CPT), or a prodrug thereof.
- 39. A method of treating fungal growth, contamination or infection, comprising contacting a plant, plant part or seed having or at risk of having fungal growth, contamination or infection, with an amount of a sequence having 90% or more identity to a sequence defined as:
(i) P1, P2, P3, P4, P5, P6 or P6, P5, P4, P3, P2, P1; wherein P1 is d- or 1-Cha, d- or 1-Nal(2), d- or 1-(Phe-2,3,4,5,6-F), d- or 1-(Phe-3,4,5F), d- or 1-(Phe-4CF3), an amino acid that occupies a similar side chain space, or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene group, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, quinazoline group in the side chain; P2 is d- or 1-Cha, d- or 1-Nal(2), d- or 1-(Phe-2,3,4,5,6-F), d- or 1-(Phe-3,4,5F), d- or 1-(Phe-4CF3), d- or 1-Bpa, d- or 1-Phe4NO2, an amino acid that occupies a similar side chain space, or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, or quinazoline group in the side chain; P3, P4, P5 are any amino acid or one or more of P3, P4, P5 is a simple carbon chain such that the distance between P2 and P6 is about the same as the distance when each of P3, P4, P5 are amino acids; P6 is d- or 1-Bpa, d- or 1-Phe4NO2, any amino acid and d- or 1-Tyr, any amino acid and d- or 1-Phe, any amino acid, or nothing; (ii) or a prodrug thereof, effective to treat the fungal growth, contamination or infection.
- 40. The method of claim 39, wherein the peptide or peptidomimetic comprises a sequence of any one of the sequences set forth in Table 1, and has anti-fungal activity.
- 41. The method of claim 39, wherein the plant, plant part or seed is contacted with the sequence locally, regionally or systemically.
- 42. The method of claim 39, wherein the plant, plant part or seed is contacted with the sequence prior to, substantially contemporaneously with or following fungal growth, contamination or infection.
- 43. The method of claim 39, wherein the plant part comprises a leaf, stem, root, flower, seed, trunk or branch.
- 44. The method of claim 39, wherein the fungal growth, contamination or infection is present at least in part on the leaf, stem, root, flower, seed, trunk or branch.
- 45. The method of claim 39, wherein the fungal growth, contamination or infection is caused by a yeast, mold or slime.
- 46. The method of claim 39, wherein the fungal growth, contamination or infection is selected from black spot, glomerelIa, ripe spot, sooty blotch, septoria leaf spot, cercospora leaf spot, rust, downy mildew, brown rot, brown patch, a smut, verrucosisl, dead arm disease, mycosphaerella leaf spot, black spot (roses), flower blight, septoria leaf blight, early and late blight, leaf mould, anthracnose, ring spot, dollar spot, northern leaf blight, alternaria and leaspora spot.
- 47. The method of claim 39, wherein the treatment results in reducing, decreasing or inhibiting fungal growth, contamination, viability or infection.
- 48. The method of claim 39, wherein the treatment results in reduced susceptibility to or recurrence of fungal growth, contamination or infection.
- 49. The method of claim 39, wherein the treatment results in inhibiting a worsening or progression of the fungal growth, contamination or infection.
- 50. The method of claim 39, further comprising contacting the plant, plant part or seed with a nucleic acid damaging agent, a nucleic acid damaging treatment, an anti-fungal agent, or an anti-fungal treatment.
- 51. The method of claim 50, wherein the agent or treatment comprises a drug.
- 52. The method of claim 51, wherein the drug comprises a chemotherapeutic drug.
- 53. The method of claim 51, wherein the drug has an anti-fungal activity or an anti-fungal function.
- 54. The method of claim 51, wherein the drug is selected from Banner Maxx, Compass Cleary's, Funginex, Immunox, Dithane, Eagle, Fore, Systhane, Topsin, captan, thiram, carboxin, mefenoxan, PCNB, fludioxonil, thiabendazole, a copper-based fungicide, a sulfur compound, a citrus oil and Bacillus subtilis.
- 55. The method of claim 51, wherein the drug comprises 5-fluorouracil (5-FU), rebeccamycin, adriamycin (ADR), bleomycin (Bleo), pepleomycin, a cisplatin derivative, camptotecin (CPT), or a prodrug thereof.
- 56. The method of claim 50, wherein the plant, plant part or seed is present in the environment, in an industrial setting, in a community setting, in a residential setting, in a commercial setting, or in an agricultural or horticultural setting.
- 57. A composition comprising an anti-fungal treatment or agent and a peptide or peptidomimetic comprising a sequence having 90% or more identity to a sequence defined as:
(i) P1, P2, P3, P4, P5, P6 or P6, P5, P4, P3, P2, P1; wherein P1 is d- or 1-Cha, d- or 1-Nal(2), d- or 1-(Phe-2,3,4,5,6-F), d- or 1-(Phe-3,4,5F), d- or 1-(Phe-4CF3), an amino acid that occupies a similar side chain space, or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene group, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, quinazoline group in the side chain; P2 is d- or 1-Cha, d- or 1-Nal(2), d- or 1-(Phe-2,3,4,5,6-F), d- or 1-(Phe-3,4,5F), d- or 1-(Phe-4CF3), d- or 1-Bpa, d- or 1-Phe4NO2, an amino acid that occupies a similar side chain space, or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, or quinazoline group in the side chain; P3, P4, P5 are any amino acid or one or more of P3, P4, P5 is a simple carbon chain such that the distance between P2 and P6 is about the same as the distance when each of P3, P4, P5 are amino acids; P6 is d- or 1-Bpa, d- or 1-Phe4NO2, any amino acid and d- or 1-Tyr, any amino acid and d- or 1-Phe, any amino acid, or nothing; (ii) or a prodrug thereof.
- 58. A composition comprising an anti-inflammatory, anti-microbial or anti-inflammatory treatment or agent and a peptide or peptidomimetic comprising a sequence having 90% or more identity to a sequence defined as:
(i) P1, P2, P3, P4, P5, P6 or P6, P5, P4, P3, P2, P1; wherein P1 is d- or 1-Cha, d- or 1-Nal(2), d- or 1-(Phe-2,3,4,5,6-F), d- or 1-(Phe-3,4,5F), d- or 1-(Phe-4CF3), an amino acid that occupies a similar side chain space, or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene group, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, quinazoline group in the side chain; P2 is d- or 1-Cha, d- or 1-Nal(2), d- or 1-(Phe-2,3,4,5,6-F), d- or 1-(Phe-3,4,5F), d- or 1-(Phe-4CF3), d- or 1-Bpa d- or 1-Phe4NO2, an amino acid that occupies a similar side chain space, or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, or quinazoline group in the side chain; P3, P4, P5 are any amino acid or one or more of P3, P4, P5 is a simple carbon chain such that the distance between P2 and P6 is about the same as the distance when each of P3, P4, P5 are amino acids; P6 is d- or 1-Bpa, d- or 1-Phe4NO2, any amino acid and d- or 1-Tyr, any amino acid and d- or 1-Phe, any amino acid, or nothing; (ii) or a prodrug thereof.
- 59. A method for identifying a compound having anti-fungal activity, comprising
(i) contacting a compund that abrogates or inhibits G2 checkpoint with a fungus; (ii) incubating the fungus with the compound; and (iii) determining viability, growth or proliferation of the fungus, wherein reduced viability, growth or proliferation of the fungus in the presence of the compound identifies the compound as having anti-fungal activity.
- 60. A method for screening for compounds having anti-fungal activity, comprising
(i) contacting a compund that abrogates or inhibits G2 checkpoint with a fungus; (ii) incubating the fungus with the compound; and (iii) determining viability, growth or proliferation of the fungus.
- 61. A method for identifying a peptide or peptidomimetic having anti-fungal activity, comprising
(i) contacting a peptide or peptidomimetic with a fungus; (ii) incubating the fungus with the peptide or peptidomimetic; and (iii) determining viability, growth or proliferation of the fungus, wherein reduced viability, growth or proliferation of the fungus in the presence of the peptide or peptidomimetic identifies the peptide or peptidomimetic as having anti-fungal activity; (iv) and wherein the peptide or peptidomimetic comprises: P1, P2, P3, P4, P5, P6 or P6, P5, P4, P3, P2, P1; wherein P1 is d- or 1-Cha, d- or 1-Nal(2), d- or 1-(Phe-2,3,4,5,6-F), d- or 1-(Phe-3,4,5F), d- or 1-(Phe-4CF3), an amino acid that occupies a similar side chain space, or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene group, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, quinazoline group in the side chain; P2 is d- or 1-Cha, d- or 1-Nal(2), d- or 1-(Phe-2,3,4,5,6-F), d- or 1-(Phe-3,4,5F), d- or 1-(Phe-4CF3), d- or 1-Bpa, d- or 1-Phe4NO2, an amino acid that occupies a similar side chain space, or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, or quinazoline group in the side chain; P3, P4, P5 are any amino acid or one or more of P3, P4, P5 is a simple carbon chain such that the distance between P2 and P6 is about the same as the distance when each of P3, P4, P5 are amino acids; P6 is d- or 1-Bpa, d- or 1-Phe4NO2, any amino acid and d- or 1-Tyr, any amino acid and d- or 1-Phe, any amino acid, or nothing; or a prodrug thereof.
- 62. A method for screening for peptides or peptidomimetics having anti-fungal activity, comprising
(i) contacting a peptide or peptidomimetic with a fungus; (ii) incubating the fungus with the peptide or peptidomimetic; and (iii) determining viability, growth or proliferation of the fungus, (iv) wherein the peptide or peptidomimetic comprises: P1, P2, P3, P4, P5, P6 or P6, P5, P4, P3, P2, P1; wherein P1 is d- or 1-Cha, d- or 1-Nal(2), d- or 1-(Phe-2,3,4,5,6-F), d- or 1-(Phe-3,4,5F), d- or 1-(Phe-4CF3), an amino acid that occupies a similar side chain space, or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene group, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, quinazoline group in the side chain; P2 is d- or 1-Cha, d- or 1-Nal(2), d- or 1-Phe2,3,4,5,6-F), d- or 1-(Phe-3,4,5F), d- or 1-(Phe-4CF3), d- or 1-Bpa, d- or 1-Phe4NO2, an amino acid that occupies a similar side chain space, or any amino acid with one or two aromatic, piperidine, pyrazine, pyrimidine, piperazine, morpholine or pyrimidine group(s), or one indole, pentalene, indene, naphthalene, benzofuran, benzothiophene, quinoline, indoline, chroman, quinoxaline, or quinazoline group in the side chain; P3, P4, P5 are any amino acid or one or more of P3, P4, P5 is a simple carbon chain such that the distance between P2 and P6 is about the same as the distance when each of P3, P4, P5 are amino acids; P6 is d- or 1-Bpa, d- or 1-Phe4NO2, any amino acid and d- or 1-Tyr, any amino acid and d- or 1-Phe, any amino acid, or nothing; or a prodrug thereof.
RELATED APPLICATIONS
[0001] This application claims priority to application serial no. 60/461,109, filed Apr. 7, 2003, which is incorprated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60461109 |
Apr 2003 |
US |